OFFICE OF FISCAL ANALYSIS
Legislative Office Building, Room 5200
Hartford, CT 06106 ↓ (860) 240-0200
AN ACT INCREASING ACCESS TO OVERDOSE REVERSAL DRUGS.
As Amended by House "A" (LCO 4795)
House Calendar No.: 42
OFA Fiscal Note
State Impact: None
FY 17 $
FY 18 $
The bill may result in a cost to municipalities, estimated to be less than $10,000 per municipality, associated with: (1) purchasing opioid antagonists, and (2) training emergency service providers to administer opioid antagonists.
This cost will vary based on the type of antagonist and the amount purchased by a municipality. Municipalities that currently purchase and administer opioid antagonists will not incur any cost as a result of the bill.
The bill will not result in a cost to the state employee and retiree health plan, municipal health plans, or the state in accordance with the Affordable Care Act (ACA).1 The state plan and fully insured municipal plans currently provide coverage in accordance with the bill.2 In addition, the bill's prescribing restrictions outlined in section 7 are not anticipated to conflict with the state health plan's 90-day refill policy for maintenance drugs.
Lastly, the bill (1) makes various other changes to current law and (2) requires a working group to be convened by the General Assembly to study opioid prescribing and report on its findings by February 1, 2017, these provisions do not result in a fiscal impact to the state or municipalities.
House “A” eliminates the original bill and its associated fiscal impact and results in the impact described above.
The Out Years
The annualized ongoing fiscal impact identified above would continue into the future subject to inflation.
1 The state employee and retiree health plan is a self-insured health plan. Pursuant to federal law, self-insured health plans are exempt from state health mandates. However, the state has traditionally adopted all state health mandates.
2 Source: Office of State Comptroller and State Dept. of Insurance